Depression Drugs Market By Medication Class 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Depression Drugs Market
Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021)
Report Code : HCR 0242
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Depression is a mood disorder that causes relentless feeling of sadness. Many factors causes depression, including brain biology and chemistry, genetics and life events such as trauma, complicated relationships, childhood experiences, loss of a loved one and any stressful situation.

The symptoms of depression are often treated by several types of medications, also known as antidepressant drugs. The most common antidepressant drugs used to treat depression are Celexa, Zoloft, Cymbalta, Prozac, Paxil, Lexapro and Pristiq.

The global depression drugs market
is growing due to rising awareness about different types of depression and their treatment. In addition, rising geriatric population, growing numbers of patients suffering from depression in developed countries such as U.S. and Canada, are also supporting to the growth of the market. However, stringent regulations for the approval of antidepressants, patent expiry of several blockbuster antidepressants drugs and strict regulations for the commercial usage of antidepressants without prescription are some of the major restraints hamper the growth of the global depression drugs market.

The global depression drugs market is segmented based on various depression medication classes, brand and geography. Based on the depression medication classes, the market is sub-segmented into monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRI), anticonvulsants, beta-blockers, tetracyclic antidepressants (TeCAs), benzodiazepines, selective serotonin reuptake inhibitors (SSRIs) and others. Amongst the medication classes, SNRI is the highest revenue segment in the current scenario.

On the basis of brand, the global depression drugs market is bifurcated into Celexa, Zoloft, Cymbalta, Prozac, Paxil, Lexapro, Pristiq and others. From the geographical perspectives, the market is segmented in North America (USA, Mexico and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia Pacific (Japan, India, China, Australia and Rest of Asia Pacific) and Rest of the World (Middle East, Latin America and Africa). North America, followed by Europe, holds major market share in the global depression drugs market due to presence of large population base suffering from various types of depression. Asia Pacific is expected to grow at a moderate growth rate during the forecast period due to increasing investment by several drug manufacturing companies owing to low wages, minimal investment, large population base and availability of skilled labour.
The dominant players in the Depression Drugs Market are:
  • Novartis International AG
  • Abbott Laboratories
  • Allergan, Plc
  • Janssen Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
1. Depression Drugs Market Overview
2. Executive Summary
3. Depression Drugs - Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End user profiling
      3.2.3. Patent Analysis
      3.2.4. Top 5 Financials Analysis
4. Depression Drugs - Market Forces
   4.1. Market Drivers
      4.1.1. Rising Awareness about Different Types of Depression
      4.1.2. Rising Geriatric Population
      4.1.3. Increasing Incidences of Depression
   4.2. Market Constraints
      4.2.1. Stringent Regulations for the Approval of Antidepressants
      4.2.2. Strict Regulations for the Commercial Usage of Antidepressants without prescription
      4.2.3.    Patent Expiry of Several Blockbuster Antidepressant Drugs
   4.3. Market Challenges
      4.3.1. Narrow Drug Pipelines
   4.4. Attractiveness of the Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Depression Drugs Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
6. Depression Drugs Market – By Medication Class
   6.1. Monoamine Oxidase Inhibitors (MAOIs)
   6.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
   6.3. Anticonvulsants
   6.4. Beta-Blockers
   6.5. Tetracyclic Antidepressants (TeCAs)
   6.6. Benzodiazepines
   6.7. Selective Serotonin Reuptake Inhibitors (SSRIs)         
7. Depression Drugs Market – By Brand
   7.1. Celexa
   7.2. Zoloft
   7.3. Cymbalta
   7.4. Prozac
   7.5. Paxil
   7.6. Lexapro
   7.7. Prestiq
   7.8. Others
8. Depression Drugs Market - Geographical Analysis
   8.1. Introduction
   8.2. North America
      8.2.1. USA
      8.2.2. Mexico
      8.2.3. Canada
   8.3. Europe
      8.3.1. Germany
      8.3.2. France
      8.3.3. U.K.
      8.3.4. Italy
      8.3.5. Spain
      8.3.6. Rest of Europe
   8.4. APAC
      8.4.1. China
      8.4.2. India
      8.4.3. Japan
      8.4.4. Australia
      8.4.5. Rest of APAC
   8.5. Rest of the World (RoW)
9. Market Entropy
   9.1. New Product Launches
   9.2. Mergers and Acquisitions,
   9.3. Collaborations, JVs and Partnerships
10. Company Profiles (Overview, Financials, SWOT Analysis – Top 05 Companies, Developments and Product Portfolio)
   10.1. Novartis International AG
   10.2. Janssen Pharmaceuticals, Inc.
   10.3. Lupin Pharmaceuticals, Inc.
   10.4. Abbott Laboratories
   10.5. Allergan, Plc
   10.6. MSI Methylation Sciences Inc.
   10.7. Luye Pharma Group Ltd.
   10.8. H. Lundbeck A/S
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports